Found: 6
Select item for more details and to access through your institution.
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
- Published in:
- Scientific Reports, 2016, p. 32946, doi. 10.1038/srep32946
- By:
- Publication type:
- Article
Pre-therapeutic fibrinogen levels are of prognostic significance in locally advanced head and neck cancer.
- Published in:
- Wiener Klinische Wochenschrift, 2016, v. 128, n. 9/10, p. 320, doi. 10.1007/s00508-016-0963-3
- By:
- Publication type:
- Article
Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer.
- Published in:
- Strahlentherapie und Onkologie, 2015, v. 191, n. 6, p. 486, doi. 10.1007/s00066-014-0803-1
- By:
- Publication type:
- Article
Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy.
- Published in:
- Strahlentherapie und Onkologie, 2015, v. 191, n. 3, p. 209, doi. 10.1007/s00066-014-0753-7
- By:
- Publication type:
- Article
Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab.
- Published in:
- Strahlentherapie und Onkologie, 2014, v. 190, n. 9, p. 832, doi. 10.1007/s00066-014-0652-y
- By:
- Publication type:
- Article